Skip to content

Registration for 2024 Annual Ataxia Conference is NOW OPEN! Early-bird discount available for a limited time.  LEARN MORE!

Gene Therapy

Desenvolvendo um interruptor liga/desliga para terapia gênica

Escrito por Dr Hannah K Shorrock Editado por Dr Larissa Nitschke Traduzido por Ana Carolina Martins Composto modificadores de “splicing” podem regular se a terapia gênica está ou não ativa A terapia gênica é uma estratégia terapêutica incrivelmente versátil que pode ser usada para tratar doenças monogênicas. A terapia gênica Read More…

Snapshot: What are adeno-associated viruses (AAV)?

Written by Paige Blair Edited by Larissa Nitschke & Celeste Suart What are adeno-associated viruses? Adeno-associated viruses, also known as AAV, are a type of virus that infects humans without causing a serious disease response. These viruses possess the unique ability to deliver DNA to specific cells in living organisms. Read More…

Developing an ON/OFF switch for gene therapy

Written by Dr Hannah K Shorrock Edited by Dr Larissa Nitschke Splice modifying compounds can regulate whether or not gene therapy is active Gene therapy is an incredibly versatile therapeutic strategy that can be used to treat monogenic disorders. Gene therapy can inactivate or silence mutant gene transcripts, edit the Read More…

Snapshot: O que é terapia genética?

Terapia genética significa utilizar ácidos nucleicos para tratar uma desordem genética. Esses ácidos nucleicos podem ser desenhados em uma variedade de formas para alcançar um mesmo propósito terapêutico. Ferramentas de terapia genética podem ser utilizadas para corrigir um gene mutante através de uma das três formas: Expressão de uma cópia saudável Read More…

Terapia génica lentiviral en ratones SCA3: Seguridad a largo plazo

Escrito por la Dra. Ambika Tewari Editado por la Dra. Hayley McLoughlin. Publicado inicialmente en el 6 de agosto de 2021. Traducción al español fueron hechas por FEDAES. La expresión lentiviral de un ARNhc contra ataxina-3 fue bien tolerada y no produjo efectos adversos medibles en ratones de tipo salvaje. La Read More…

Regulating ataxin-1 expression as a therapeutic avenue for SCA1

Written by Dr. Hannah Shorrock   Edited by Dr. Hayley McLoughlin Nitschke and colleagues identify a microRNA that regulates ataxin-1 levels and rescues motor deficits in a mouse model of SCA1 What if you could use systems already in place in the cell to regulate levels of toxic proteins in disease? Read More…

Discovery of a new molecular pathway in spinocerebellar ataxia 17

Written by Dr. Sriram Jayabal Edited by Dr. Ray Truant A potential new pathway for SCA17: gene therapy that in mice restores a critical protein deficit protects brain cells from death in SCA17. Neurodegenerative ataxias are a group of brain disorders that progressively affect one’s ability to make fine coordinated Read More…

New Strategy for Reducing Ataxin-1 Levels Shows Promise

Written by Carrie A. Sheeler Edited by Dr. Ronald A.M. Buijsen RNAi reduces levels of disease-causing Ataxin-1 in SCA1 model mice, easing symptoms of disease when injected both before and after symptom onset. Lowering the amount of the disease-causing mutant Ataxin-1 protein in affected cells and tissues improves symptoms of Read More…

Translate »

Join the Ataxia community today!

Become a free member for exclusive content from NAF.